Company

Vir Biotechnology and Gilead Strike Collaboration to Engineer Three PRO‑XTEN Dual‑Masked T‑Cell Engagers – Deal Worth Up to USD 1.88 Billion in Milestones
Gilead SciencesMulti-specific antibodies

Vir Biotechnology and Gilead Strike Collaboration to Engineer Three PRO‑XTEN Dual‑Masked T‑Cell Engagers – Deal Worth Up to USD 1.88 Billion in Milestones

Vir Biotechnology, Inc. (NASDAQ: VIR) announced a collaboration and license agreement with Gilead Sciences to discover and engineer three novel PRO‑XTEN dual‑masked T‑cell engager (TCE) development candidates targeting selected solid…

Merck Inaugurates ADVANCE Research Facility in West Point, Pennsylvania – AI‑Powered Automation Hub to Accelerate Global Drug Development

Merck Inaugurates ADVANCE Research Facility in West Point, Pennsylvania – AI‑Powered Automation Hub to Accelerate Global Drug Development

Chipscreen Biosciences Secures NMPA IND Acceptance for CS23546 – Oral Small‑Molecule PD‑L1 Inhibitor Advancing in Relapsed or Refractory Lymphoma

Chipscreen Biosciences Secures NMPA IND Acceptance for CS23546 – Oral Small‑Molecule PD‑L1 Inhibitor Advancing in Relapsed or Refractory Lymphoma

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Fosun Pharma Secures Exclusive China Rights to InxMed's FAK Inhibitors for Solid Tumor Treatment
CancerFosun Pharmaceutical

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

CAR-TJ&J

Johnson & Johnson Terminates Two CAR-T Development Programs Amid Portfolio Prioritization

FinanceHarbour BioMed

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Huadong MedicineMarket approval filings

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Show More